Advanced Science · 2019 · 165 citations · 41 references
MedicineOncologyPharmacologyDrug DeliveryImmunotherapyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesLiposome-based DeliveryTargeted Cancer TherapyTumor Immune MicroenvironmentAdaptive Antitumor ImmunityBreast Cancer ChemotherapyCancer Vaccine Delivery SystemsChemotherapy-induced Immunogenic Cell DeathDendritic Cell-t Cell InteractionImmunogenic Cell Death InductionInnate Antitumor ImmunityLiposome Adjuvants
Abstract Chemotherapy turns tumor cells into “tumor vaccines” by immunogenic cell death (ICD). However, it remains a challenge to exploit chemotherapy‐induced “tumor vaccines” for solid cancer immunotherapy due to the inefficient effector T cells activation and tumor microenvironment immunosuppression. Here, a matrix metalloprotease 2 responsive liposome (PEG‐FA‐Lip) composed of cleavable PEG chains covering the folate (FA)‐modified liposome is developed to deliver ICD inducer doxorubicin. In breast cancer‐bearing mice, PEG‐FA‐Lip targets both 4T1 breast cancer cells and M2‐tumor associated macrophages (M2‐TAMs) via FA‐receptor mediated endocytosis, resulting in abundant “tumor vaccines” and efficient elimination of M2‐TAMs. The combination of local cytosine‐phosphate‐guanine (CpG) therapy facilitates PEG‐FA‐Lip induced “tumor vaccines” to effectively arouse systematic effector T cells immune response through promoting dendritic cell maturation and immunostimulatory cytokines secretion. The simultaneous elimination of M2‐TAMs ensures the activated effector T cells exert antitumor immunity within tumor via decreasing immunosuppressive cytokines secretion and tumor infiltration of Treg cells. After receiving the combined treatment, 30.1% of breast cancer‐bearing mice (initial tumor volume > 100 mm 3 ) achieves the goal of tumor eradication. Remarkably, this combination therapy greatly inhibits lung metastasis and controls the growth of already metastasized breast cancers (initial tumor volume > 100 mm 3 ).
41
Cancer immunotherapy: moving beyond current vaccines
Steven A. Rosenberg, James C. Yang, Nicholas P. Restifo · Nature Medicine · 2004 · 3K citations · Full text
Medicine, Immunology, Oncology +14
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Steven D. Perrault, Carl Walkey, Travis L. Jennings et al. · Nano Letters · 2009 · 1.5K citations
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Noëlia Casares, Marie O. Péquignot, Antoine Tesnière et al. · The Journal of Experimental Medicine · 2005 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17